SOURCE: Lpath, Inc.

October 31, 2007 15:16 ET

Lpath to Present at BIOCOM 2007

SAN DIEGO, CA--(Marketwire - October 31, 2007) - Lpath, Inc. (OTCBB: LPTN), the category leader in therapeutic agents against bioactive lipids, announced that its chief executive officer, Scott R. Pancoast, will provide an overview and status update of the company at BIOCOM's Investor Conference 2007 on Thursday, November 1, 2007 at 3:30 p.m. PDT. The conference is being held at The San Diego Marriott Del Mar from October 31 to November 2.

A live audio webcast of the presentation will be available on Lpath's website at A replay of the presentation will be available approximately one hour after the live webcast concludes and will be archived for 30 days.

The BIOCOM Investor Conference 2007 will highlight investment opportunities represented by Southern California's top life science companies to top institutional and retail investors. The conference will include plenary sessions, one-on-one meetings and company presentations. Conference details are available online at the events section of the BIOCOM website at


BIOCOM is a premier life science industry association representing more than 550 member companies in Southern California. The association focuses on initiatives that positively influence the growth of the life science industry, including capital formation, public policy, workforce development, and scientific discovery and development.

About Lpath

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP™ (the systemic formulation of humanized form of Sphingomab™) is an antibody against S1P that holds promise for the treatment of cancer and other diseases. A second product candidate, iSONEP™ (the ocular formulation of humanized Sphingomab), has demonstrated superior results in various preclinical AMD and retinopathy models. Lpath's third product candidate, Lpathomab™, is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2™ drug-discovery engine, which the company is using to add to its pipeline. For more information, visit

Contact Information

  • Contact:

    Scott Pancoast
    (858) 678-0800 x104
    Email Contact

    Investor Relations
    Liolios Group, Inc.
    Scott Liolios or Ron Both
    (949) 574-3860